PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced new results showing complete hematologic and molecular responses with ropeginterferon alfa-2b (marketed as BESREMi®
(ropeginterferon alfa-2b-njft)) treatment in both high and low-risk polycythemia vera (PV) patients. The data suggest potential clinical benefits from earlier treatment intervention with ropeginterferon alfa2b¹. The presentation took place during the 64th American Society of Hematology (ASH) Annual Meeting on Monday, December 12, 2022.

For the full release please visit us.pharmaessentia.com